Drug Database · Clinicians

Dapagliflozin

Brands (100) Catania, Dapazin, Daphix…Show all

US brand (reference label): FARXIGA; not a Philippine-registered brand.

Blood glucose lowering drug (sodium-glucose co-transporter 2 (SGLT2) inhibitor)); Sodium-glucose co-transporter 2 (SGLT2) inhibitor; and others PH FDA category

Do not start if eGFR <25Rx · Prescription drug135 PH productsPNF-listedPhilHealth GAMOTVAT-exempt (some products) Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 72ad22ae-efe6-4cd6-a302-98aaee423d69, version date June 3, 2026 (FARXIGA · AstraZeneca Pharmaceuticals LP). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
  • To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.
  • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.
  • As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE FARXIGA (dapagliflozin) is indicated:

  • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
  • To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.
  • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.
  • As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Limitations of Use
  • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1)].
  • FARXIGA is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m². FARXIGA is likely to be ineffective in this setting based upon its mechanism of action.
  • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations. FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated:
  • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. (1)
  • To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. (1)
  • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors. (1)
  • As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. (1) Limitations of use:
  • Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. (1)
  • Not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m². FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. (1)
  • Not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for the treatment of kidney disease. FARXIGA is not expected to be effective in these populations. (1)

Contraindications

  • History of serious hypersensitivity to dapagliflozin or any excipient
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS FARXIGA is contraindicated in patients with a history of a serious hypersensitivity reaction to dapagliflozin or any of the excipients in FARXIGA. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with FARXIGA [see Adverse Reactions (6.1)]. • History of serious hypersensitivity reaction to dapagliflozin or any of the excipients in FARXIGA. (4)

Dosing: Adult

  • CKD at risk of progression; heart failure; cardiovascular risk in type 2 diabetes: 10 mg once daily
  • Glycemic control, type 2 diabetes: Start 5 mg once daily; may increase to 10 mg
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • • Assess renal function prior to initiation and then as clinically indicated. Assess volume status and correct volume depletion before initiating. (2.1)
  • • To improve glycemic control, the recommended starting dosage is 5 mg orally once daily. Dosage can be increased to 10 mg orally once daily for additional glycemic control. (2.2)
  • • For all other indications, the recommended dosage is 10 mg orally once daily. (2.3)
  • • See full prescribing information for dosage recommendations in patients with renal impairment. (2.2, 2.3)
  • • Withhold FARXIGA for at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. (2.4)
2.1 Testing Prior to Initiation

2.1 Testing Prior to Initiation of FARXIGA

  • Assess renal function prior to initiation of FARXIGA and then as clinically indicated [see Warnings and Precautions (5.2)].
  • Assess volume status. In patients with volume depletion, correct this condition before initiating FARXIGA [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5, 8.6)].
2.2 Recommended Dosage for Glycemic Control in Adults and Pediatric Patients Aged 10 Years

2.2 Recommended Dosage for Glycemic Control in Adults and Pediatric Patients Aged 10 Years and Older with Type 2 Diabetes Mellitus In adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, the recommended starting dosage of FARXIGA is 5 mg orally once daily to improve glycemic control. For additional glycemic control, the dosage can be increased to 10 mg orally once daily.

For Adult and Pediatric Patients with Type 2 Diabetes Mellitus and Renal Impairment:

  • The recommended dosage for FARXIGA in patients with an eGFR greater than or equal to 45 mL/min/1.73 m² is the same as the recommended dosage in patients with normal renal function.
  • FARXIGA is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m². FARXIGA is likely to be ineffective to improve glycemic control in this setting based upon its mechanism of action.
2.3 Recommended Dosage for Other Indications in Adults

2.3 Recommended Dosage for Other Indications in Adults The recommended dosage of FARXIGA is 10 mg orally once daily in adults for the following indications:

  • To reduce the risk of sustained eGFR decline, end-stage kidney disease (ESKD), CV death, and hospitalization for heart failure (hHF) in patients with chronic kidney disease at risk of progression.
  • To reduce the risk of CV death, hHF, and urgent heart failure visit in patients with heart failure.
  • To reduce the risk of hHF in patients with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors. For Adults with Renal Impairment Receiving FARXIGA for Indications Other than Glycemic Control:
  • The recommended dosage of FARXIGA in patients with an eGFR greater than or equal to 25 mL/min/1.73 m² is the same as the recommended dosage in patients with normal renal function.
  • Initiation with FARXIGA is not recommended in patients with an eGFR less than 25 mL/min/1.73 m².
  • If the eGFR falls below 25 mL/min/1.73 m² while receiving treatment with FARXIGA, patients may continue FARXIGA 10 mg orally once daily to reduce the risk of eGFR decline, ESKD, CV death and hHF.
2.4 Temporary Interruption for Surgery Withhold

2.4 Temporary Interruption for Surgery Withhold FARXIGA for at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. Resume FARXIGA when the patient is clinically stable and has resumed oral intake [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].

2.5 Recommendations Regarding Missed Dose

2.5 Recommendations Regarding Missed Dose

  • If a dose is missed, instruct patients to take the dose as soon as possible.
  • Advise patients not to double up the next dose.

Dosing: Altered kidney function

Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. For kidney and heart protection the US label allows starting at an estimated glomerular filtration rate (eGFR) of 25 mL/min/1.73 m2 or higher and continuing below 25; for glucose lowering alone it is not recommended below eGFR 45. Guidelines (KDIGO 2024, ADA-KDIGO 2022) support starting at eGFR ≥20 and continuing until intolerance or kidney replacement therapy.

Kidney function measure: Label uses eGFR (mL/min/1.73 m2).

Show full dosing details
eGFR ≥60
No adjustment. Chronic kidney disease (CKD), heart failure and cardiovascular indications: 10 mg once daily. Glycemic control: start 5 mg once daily.
eGFR 30–59
CKD, heart failure and cardiovascular indications: 10 mg once daily. Glycemic control: not recommended if eGFR <45 (likely ineffective).
eGFR 15–29
eGFR 25–29: may start 10 mg once daily for CKD, heart failure or cardiovascular indications. eGFR <25: do not start; patients already on it may continue 10 mg once daily (label). Not for glycemic control. Guidelines (KDIGO 2024, ADA-KDIGO 2022) support starting SGLT2 inhibitors at eGFR ≥20 (off-label for dapagliflozin at 20–24) and continuing below 20 until intolerance or kidney replacement therapy.
eGFR <15 (not on dialysis)
Do not start. May continue 10 mg once daily if started earlier (label: continue if eGFR falls below 25). Not for glycemic control.
Hemodialysis (intermittent)
Not studied; trials did not enroll patients on dialysis. Trial patients who started dialysis were not required to stop (label). Effect of hemodialysis on exposure is unknown. Guidelines advise continuing until kidney replacement therapy begins (ADA-KDIGO); not effective for glucose lowering on dialysis. Specialist input.
Peritoneal dialysis
Not studied (label). Insufficient data: specialist input.
CRRT
No data in label. Insufficient data: specialist input; usually held in acute illness.
  • Dialyzable? Unknown: removal by hemodialysis has not been studied (label).
  • Monitoring Assess kidney function and volume status before starting; correct volume depletion. Expect an early small eGFR dip. Withhold at least 3 days before surgery or prolonged fasting (label); watch for ketoacidosis.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Usual dose (glycemic indication).
eGFR 30–59
eGFR 45–59: usual dose. eGFR <45: not recommended for glycemic control (label applies to adult and pediatric patients).
eGFR 15–29
Not recommended for glycemic control (eGFR <45).
eGFR <15 (not on dialysis)
Not recommended for glycemic control (eGFR <45).
Hemodialysis (intermittent)
Not studied; not recommended.
Peritoneal dialysis
Not studied; not recommended.
CRRT
No data.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

8.6 Renal Impairment FARXIGA was evaluated in 4304 adult patients with chronic kidney disease (eGFR 25 to 75 mL/min/1.73 m2) in the DAPA-CKD trial. FARXIGA was also evaluated in 1926 adult patients with an eGFR of 30 to 60 mL/min/1.73 m2 in the DAPA-HF trial. The safety profile of FARXIGA across eGFR subgroups in these studies was consistent with the known safety profile [see Adverse Reactions (6.1) and Clinical Studies (14.4, 14.5)].

FARXIGA was evaluated in two glycemic control adult trials that included patients with type 2 diabetes mellitus with moderate renal impairment (an eGFR of 45 to less than 60 mL/min/1.73 m2 [see Clinical Studies (14.1)], and an eGFR of 30 to less than 60 mL/min/1.73 m2, respectively). Patients with diabetes and renal impairment using FARXIGA may be more likely to experience hypotension and may be at higher risk for acute kidney injury secondary to volume depletion.

In the trial of adult patients with an eGFR 30 to less than 60 mL/min/1.73 m2, 13 patients receiving FARXIGA experienced bone fractures compared to none receiving placebo. Use of FARXIGA for glycemic control in patients without established CV disease or CV risk factors is not recommended when eGFR is less than 45 mL/min/1.73 m2 [see Dosage and Administration (2.1)].

Efficacy and safety trials with FARXIGA did not enroll patients with an eGFR less than 25 mL/min/1.73 m² or on dialysis. Once enrolled in the DAPA-CKD and DELIVER trials, adult patients were not required to discontinue therapy if eGFR fell below 25 mL/min/1.73 m² or if dialysis was initiated. Once enrolled in the DAPA-HF trial, adult patients were not required to discontinue therapy if eGFR fell below 30 mL/min/1.73 m² or if dialysis was initiated [see Dosage and Administration (2.3) and Clinical Studies (14.4, 14.5)].

Patients with Renal Impairment At steady state (20 mg once daily dapagliflozin for 7 days), adult patients with type 2 diabetes with mild, moderate, or severe renal impairment (as determined by eGFR) had geometric mean systemic exposures of dapagliflozin that were 45%, 100%, and 200% higher, respectively, as compared to patients with type 2 diabetes mellitus with normal renal function. There was no meaningful difference in exposure between patients with chronic kidney disease with and without type 2 diabetes.

Higher systemic exposure of dapagliflozin in patients with type 2 diabetes mellitus with renal impairment did not result in a correspondingly higher 24-hour urinary glucose excretion. The steady-state 24-hour urinary glucose excretion in patients with type 2 diabetes mellitus and mild, moderate, and severe renal impairment was 42%, 80%, and 90% lower, respectively, than in patients with type 2 diabetes mellitus with normal renal function.

The impact of hemodialysis on dapagliflozin exposure is not known [see Warnings and Precautions (5.2), Use in Specific Populations (8.6), and Clinical Studies (14)]

Dosing: Hepatic impairment

8.7 Hepatic Impairment No dose adjustment is recommended for patients with mild, moderate, or severe hepatic impairment. However, the benefit-risk for the use of dapagliflozin in patients with severe hepatic impairment should be individually assessed since the safety and efficacy of dapagliflozin have not been specifically studied in this population [see Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Approved ages
Type 2 diabetes glycemic control: 10 years and older. Not established under 10 years, and not established in children for CKD, heart failure or cardiovascular indications (label).
Usual dose
Type 2 diabetes, 10 years and older: start 5 mg orally once daily (label gives a fixed dose, not mg/kg). Maximum per label 10 mg once daily.
Maximum dose
10 mg once daily (adult maximum).
Neonates
Neonates: not applicable (not established under 10 years).

Pediatric kidney-protection use is not established; any such use is specialist off-label practice.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of FARXIGA as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus have been established in pediatric patients aged 10 years and older. Use of FARXIGA for this indication is supported by a 26-week placebo-controlled trial with a 26-week extension in 157 pediatric patients aged 10 to 17 years with type 2 diabetes mellitus, pediatric pharmacokinetic data, and trials in adults with type 2 diabetes mellitus [see Clinical Pharmacology (12.3) and Clinical Studies (14.1, 14.2)].

The safety profile observed in the placebo-controlled trial in pediatric patients with type 2 diabetes mellitus was similar to that observed in adults [see Adverse Reactions (6.1)]. The safety and effectiveness of FARXIGA for glycemic control in type 2 diabetes mellitus have not been established in pediatric patients less than 10 years of age.

The safety and effectiveness of FARXIGA have not been established in pediatric patients to reduce the risk of [see Indications and Usage (1)]:

  • sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression.
  • CV death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure.
  • hospitalization for heart failure in patients with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use No FARXIGA dosage change is recommended based on age. A total of 1424 (24%) of the 5936 FARXIGA-treated patients were 65 years and older and 207 (3.5%) patients were 75 years and older in a pool of 21 double-blind, controlled, clinical trials assessing the efficacy of FARXIGA in improving glycemic control in type 2 diabetes mellitus.

After controlling for level of renal function (eGFR), efficacy was similar for patients under age 65 years and those 65 years and older. In patients ≥65 years of age, a higher proportion of patients treated with FARXIGA for glycemic control had adverse reactions of hypotension [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)].

In the DAPA-CKD, DAPA-HF and DELIVER trials, safety and efficacy were similar for patients aged 65 years and younger and those older than 65. In the DAPA-HF study, 2714 (57%) out of 4744 patients with HFrEF were older than 65 years. In the DELIVER study, 4759 (76%) out of 6263 patients with heart failure (LVEF >40%) were older than 65 years.

In the DAPA-CKD study, 1818 (42%) out of 4304 patients with CKD were older than 65 years.

Dosage forms

Philippines

  • Film-coated tablet: 5 mg, 5 mg/1 g, 10 mg
  • Film-coated-tablet: 10 mg
  • Fiim-coated tablet: 10 mg
  • Tablet: 10 mg

Registered products in the Philippines

135 products registered with the Food and Drug Administration (FDA) Philippines list Dapagliflozin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Dapaglifozin (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products135
Philippine FDA-registered products for Dapagliflozin
Package insert
AcadiaDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Kaufmann Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-15342-02
Jun 25, 2029
AplivaDapagliflozin
10mg TabletAluminum Foil and Cold form Blister Foil Pack x 7's (Box of 28's)
RxVAT-exempt
Alembic Pharmaceuticals LimitedIndia
Natrapharm Inc.
DR-XY49506
Sep 10, 2030
AplivaDapagliflozin
5 mg Film-Coated TabletAluminum Foil and Cold form Blister Foil Pack x 7's (Box of 28's)
RxVAT-exempt
Alembic Pharmaceuticals LimitedIndia
Natrapharm Inc.
DR-XY49507
Sep 10, 2030
AstigetDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Getz Pharma (Phils.). Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-10721-08
Nov 11, 2031
AzaplipDapagliflozin
10 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-17802
Mar 12, 2031
AzflozDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading, Inc.
DRP-11789-06
Apr 29, 2027
BrankaDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Helande Kidney Care Inc.Importer: AMB HK Enterprises Inc.
DRP-15342-04
Jun 25, 2029
CardioglyDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Health Prescription, Inc.Importer: Ambica International Corporation
DRP-15483-03
Jul 16, 2029
CataniaDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Corbridge Group Phils., Inc.
DR-XY49007
Feb 22, 2029
CataniaDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister pack of 10’s (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Corbridge Group Phils., Inc.Importer: Ollen Pharma Trading, Inc.
DRP-11789-07
Apr 29, 2027
CataniaDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack X 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Private LimitedIndia
Corbridge Group Phils., IncImporter: AMB HK Enterprises Inc.
DRP-15342-01
Jun 25, 2029
CataniaDapagliflozin
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Corbridge Group Phils., Inc.
DR-XY49008
Feb 22, 2029
DafadinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt.Ltd.India
Medchoice Endocrine Group, Inc.Importer: Ambica International Corporation
DRP-15483-11
Jul 16, 2029
DaflozinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Phil Asia Pharma Inc.Importer: Ambica International Corporation
DRP-15483-05
Jul 16, 2029
DafozeinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-15483-08
Jul 16, 2029
Dagliflo 10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15342
Jun 25, 2029
Dagliflo 5Dapagliflozin (as propanediol monohydrate)
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15343
Jun 25, 2029
DahexaDapagliflozin
10 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-17802-01
Mar 12, 2031
DajioDapagliflozin
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DRP-16170
Mar 16, 2027
DAPA-10Dapagliflozin
10 mg Film Coated tabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Phils., Inc.
DR-XY47825
Mar 16, 2027
DAPA-5Dapagliflozin
5 mg Film Coated tabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Phils., Inc.
DR-XY47824
Mar 16, 2027
Dapa-ZDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Trader: Innogen Pharmaceuticals, Inc.
DRP-10721
Nov 11, 2036
DapacureDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Pharma Hub CorporationImporter: Ambica International Corporation
DRP-15483-10
Jul 16, 2029
Dapadrate-10Dapagliflozin (as propanediol monohydrate)
10 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-17359
Nov 20, 2030
DapafastDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Fluorish PharmaIndia
Speed Med Pharmaceuticals Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-15726
Sep 10, 2029
DapafastDapaglifozinVariant spelling
5 mg Film-Coated Tablet: Alu-Alu Blister Pack x 10's (Box of 30's)
Rx
Flourish PharmaIndia
Speed Med Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-16535
Apr 15, 2030
Dapafloxa-10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Ratnatris Pharmaceuticals Private LimitedIndia
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-16503-01
Apr 2, 2030
DapafozDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.
DRP-11789-10
Apr 29, 2027
DapagDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-15483-06
Jul 16, 2029
Dapaglif 10Dapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Orange Biotec Inc.
DRP-15710
Sep 4, 2029
DapagliferDapagliflozin
10 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
Ferma Drug Enterprises
DRP-17802-03
Mar 12, 2031
DapagniumDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blsiter Pack x 10's (Box of 30's)
RxVAT-exempt
4Care Lifescience Private LimitedIndia
Titanium PharmaImporter: Aglobal Care, Inc.
DRP-17907-03
Apr 7, 2031
Dapaloz 10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Ratnatris Pharmaceuticals Private LimitedIndia
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-16503-02
Apr 2, 2030
Dapaloz 10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Saludcare (I) Pvt. Ltd.India
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-17808-01
Mar 12, 2031
Dapamac 10Dapagliflozin
10 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
Macleods Pharmaceuticals Philippines, Inc.
DR-XY49408
May 30, 2030
DapanavDapagliflozin (as propanediol monohydrate)
10mg Film-coated tabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
4Care Lifescience Private LimitedIndia
Rexmed Pharmaceutical SalesImporter: Aglobal Care, Inc.
DRP-17907-04
Apr 7, 2031
DapaquisDapagliflozin (as propanediol)
10 mg Film-Coated TabletWhite round HDPE plastic bottle with blue child- resistant cap x 30's (Box of 30's)
RxVAT-exempt
Cipla Ltd. (Unit III)India
SMHP Pharmaceuticals Incorporated
DRP16044
Oct 21, 2029
DaparichDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Medirich Pharma Distribution Corp.Trader: ULTRAMED PHARMA, INC.
DRP-14984-05
Aug 2, 2028
Dapasaph-10Dapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Sai Parenterals Ltd.India
Ollen Pharma Trading Inc.
DRP-11789
Jun 16, 2031
Dapasaph-G10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated Tablet
RxVAT-exempt
Global Pharma Healthcare Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-17604
Feb 6, 2031
Dapasaph-G5Dapagliflozin (as propanediol monohydrate)
5 mg Film-Coated Tablet
RxVAT-exempt
Global Pharma Healthcare Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-17605
Feb 6, 2031
DapaseaDapagliflozin
10 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
The Acme Laboratories LimitedBangladesh
SEA-King Pharma Inc.Importer: Uno Medique Pharmaceuticals, OPC
DR-XY49530
Oct 1, 2030
Dapastal-10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-15483
Jul 16, 2029
DapasureDapagliflozin
Film-Coated Tablet 10 mgAlu/Alu Blister Pack x 10’s (Box of 30’s and 100's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Rinon Care Pharma, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-17182-01
Oct 16, 2030
Dapator-10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation
DRP-15483-19
Jul 16, 2029
DAPATRIS-10Dapagliflozin (as Propanediol Monohydrate)
10 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-16564
Apr 29, 2030
Dapatris-5Dapagliflozin (as propanediol monohydrate)
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.
DRP-17766
Feb 27, 2031
DapavelDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Philippine Home Pharmaceuticals
DR-XY49696
Apr 23, 2032
DapavelDapagliflozin
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Philippine Home Pharmaceuticals
DR-XY49697
Apr 23, 2032
DapavidDapagliflozin
10mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Hovid Inc.Trader: Hovid Bhd.
DRP-14039
Jun 7, 2028
DapavireDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blsiter Pack x 10's (Box of 30's)
RxVAT-exempt
4Care Lifescience Private LimitedIndia
Solvire Life IncorporatedImporter: Aglobal Care, Inc.
DRP-17907-02
Apr 7, 2031
DapazinDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY49139
Jul 26, 2029
DapazinDapagliflozin
10 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.
DRP-16241
Jul 26, 2029
DapazinDapagliflozin
10mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ajanta Pharma Philippines Inc.Importer: Ollen Pharma Trading Inc.
DRP-11789-01
Apr 29, 2027
DapazolinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Ratnatris Pharmaceuticals Private LimitedIndia
Vitalife Pharma & Medical Supply Inc.Importer: Medinova Pharmaceutical Inc.
DRP-16503-05
Apr 2, 2030
Dapazox 10Dapagliflozin
10 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit III)India
Camber Pharmaceuticals, Inc.
DRP-16437
Mar 11, 2030
Dapazox 5Dapagliflozin
5 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Hetero Labs Limited (Unit III)India
Camber Pharmaceuticals, Inc.
DRP-16438
Mar 11, 2030
DapflozDapagliflozin (as propanediol monohydrate)
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Towa Pharma Private LimitedIndia
Euroasia Pharmaceuticals, Inc
DRP-18072
Apr 30, 2031
Dapfloz-10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Towa Pharma Private LimitedIndia
Euroasia Pharmaceuticals, Inc
DRP-18071
Apr 30, 2031
DaphixDapagliflozin (as propanediol monohydrate)
10 mg Film Coated TabletAlu/Alu Blister Pack x 15's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-15429
Jul 8, 2029
DaphixDapagliflozin
10 mg Film Coated TabletAlu/Alu Blister Pack x 15's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc.
DRP-15956
Oct 3, 2029
DaphixDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Oxpharm Inc.Importer: AMB HK Enterprises Inc.
DRP-16601
May 20, 2030
Dapiflozin M 5/1000Dapagliflozin
5mg/1g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd.
DRP-16935
Aug 27, 2030
Daptica 10Dapagliflozin
10 mg Film-Coated TabletAlu-Alu blister pack x 8tablets (box of 24 tablets)
RxVAT-exempt
Glenmark Pharmaceuticals LimitedIndia
Glenmark Philippines, Inc.
DRP-12914
Oct 28, 2027
Dhafag-TenDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.
DRP-11789-04
Apr 29, 2027
DhaploffDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.
DRP-11789-08
Apr 29, 2027
Diabezin-10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Ratnatris Pharmaceuticals Private LimitedIndia
Medinova Pharmaceutical Inc.
DRP-16503
Apr 2, 2030
Diabezin-10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Saludcare (I) Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-17808
Mar 12, 2031
Diabitor®10Dapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Justright Healthcare Inc.Trader: Ultramed Pharma, Inc.
DRP-14984-01
Aug 2, 2028
DiadellDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Flourish PharmaIndia
NAB Trading Corp.Importer: Biophil Medical Equipment And Supplies Trading
DRP-15726-01
Sep 10, 2029
Diasaph-GE10Dapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-17182
Oct 16, 2030
DihesinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Private LimitedIndia
McGraw Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-15342-10
Jun 25, 2029
DihesinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Mc Graw Pharma Inc.Importer: Ambica International Corporation
DRP-15483-14
Jul 16, 2029
FlosazinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Asterzenmed Inc.Importer: Ambica International Corporation
DRP-15483-02
Jul 16, 2029
FloxindaDapagliflozin (as Propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Private LimitedIndia
Lakeside Pharmaceuticals Phil., IncImporter: AMB HK Enterprises Inc.
DRP-15342-05
Jun 25, 2029
ForxigaDapagliflozin (as propanediol monohydrate)
5 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
AstraZeneca Pharmaceuticals LPU.S.A
AstraZeneca Pharmaceuticals (Phils.), Inc.Trader: AstraZeneca UK Ltd.
DRP-9942
Oct 19, 2028
Forxiga®Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
AstraZeneca Pharmaceuticals LPU.S.A
AstraZeneca Pharmaceuticals (Phils.), Inc.
DRP-9916
Oct 19, 2028
ForzinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Private LimitedIndia
CCL Pharmaceuticals (Philippines), Inc.Importer: AMB HK Enterprises Inc.
DRP-15342-07
Jun 25, 2029
ForzinDapagliflozin (as propanediol monohydrate)
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Private LimitedIndia
CCL Pharmaceuticals (Philippines), Inc.Importer: AMB HK Enterprises Inc.
DRP-15343-01
Jun 26, 2029
ForzinormDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DR-XY48830
Aug 2, 2028
ForzinormDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DRP-14984
Aug 2, 2028
G-DAPADapagliflozin
10 mg Film-Coated-TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, IncPhilippines
Gx International,Inc.Trader: Ultramed Pharma, Inc
DRP-14984-03
Aug 2, 2028
GiflomanDapagliflozin
10 mg Film-Coated-TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Littman Drug CorporationTrader: Ultramed Pharma, Inc.
DRP-14984-06
Aug 2, 2028
GlidapaDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Alkem Laboratories CorporationImporter: Ambica International Corporation
DRP-15483-09
Jul 16, 2029
GlifixyDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Totalcare Pharma Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-10721-04
Nov 11, 2031
GlifquinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Macropharma CorporationImporter: Ambica International Corporation
DRP-15483-15
Jul 16, 2029
GlucardalDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
D&G PharmaImporter: Ambica International Corporation
DRP-15483-23
Jul 16, 2029
Glucodap®Dapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, IncPhilippines
Metro Pharma Philippines Inc.Trader: Ultramed Pharma, Inc.
DRP-14984-02
Aug 2, 2028
GlucosurDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.
DRP-11789-03
Apr 29, 2027
GlucoviveDapagliflozin (as Propanediol monohydrate)
10 mg Film-Coated TabletAlu/ Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Private LimitedIndia
Healol Pharma CoprorationImporter: Amb Hk Enterprises Inc.
DRP-15342-08
Jun 25, 2029
GlucoviveDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 15's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Healol Pharma CorporationImporter: AMB HK Enterprises Inc.
DRP-15956-01
Oct 4, 2029
GlucusuriaDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.
DRP-11789-02
Apr 29, 2027
GlurexaDapagliflozin
10 mg Film-Coated TabletAlu/ Alu blister pack x 8 tablets (Box of 24 tablets)
RxVAT-exempt
Glenmark Pharmaceuticals LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Glenmark Philippines, Inc.
DRP-12914-01
Oct 28, 2027
Glydap10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Ratnatris Pharmaceuticals Private LimitedIndia
GA2 Pharmaceutical, IncImporter: Medinova Pharmaceutical, Inc.
DRP-16503-04
Apr 2, 2030
GlyhartDapagliflozin
10 mg Film-Coated TabletsAlu-Alu Blister Pack x 7' s (Box of 28' s)
RxVAT-exempt
Inventia Healthcare LimitedIndia
UNILAB, Inc
DRP-14152
Jun 30, 2028
Invaflozin 10Dapagliflozin
10mg Film-Coated TabletAlu-Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Healol Pharma Corporation
DR-XY48945
Dec 14, 2028
Invaflozin 5Dapagliflozin
5mg Film-coated TabletAlu-Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Healol Pharma Corporation
DRP-14725
Dec 14, 2028
KidniflozinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Scriptmed, Inc.Importer: Ambica International Corporation
DRP-15483-13
Jul 16, 2029
LupizinDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Multicare Pharmaceuticals Phils. Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-10721-10
Nov 11, 2031
NoneDapagliflozin (as propanediol monohydrate)
10 mg FiIm-Coated TabletAlu/Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
AstraZeneca Pharmaceuticals LPUSA
Globo Asiatico Enterprises, Inc.Importer: AstraZeneca Pharmaceuticals (Phils.), Inc.Trader: AstraZeneca UK Limited
DRP-9916-02
Feb 10, 2029
NoneDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading, Inc.
DRP-11789-05
Apr 29, 2027
NoneDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt.Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-15483-04
Jul 16, 2029
NoneDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Reta DrugImporter: Ambica International Corporation
DRP-15483-17
Jul 16, 2029
NoneDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Dyna Drug CorporationImporter: Ambica International Corporation
DRP-15483-20
Jul 16, 2029
NoneDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-15483-24
Jul 16, 2029
NoneDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-15483-25
Jul 16, 2029
NoneDapagliflozin
10 mg Film-Coated TabletAlu / Alu Blister Pack x 15’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
South Star DrugImporter: AMB HK Enterprises Inc.
DRP-15956-02
Oct 4, 2029
NoneDapagliflozin
10 mg Film-coated TabletAlu/Alu Blister Pack x 10’s (Box of 30&#39;s)
RxVAT-exempt
SRI Krishna Pharmaceuticals Ltd.India
Ritemed Phils., Inc.Trader: Pinnacle Life Sciences Private Limited
DRP-18591
Aug 3, 2031
NoneDapagliflozin
10 mg Film-Coated-TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.Trader: Ultramed Pharma, Inc.
DRP-14984-04
Aug 2, 2028
Paglozin-10Dapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
4Care Lifescience Private LimitedIndia
Aglobal Care, Inc.
DRP-17907
Apr 7, 2031
PalonexDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Medlink Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-15483-16
Jul 16, 2029
PremglyxDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt LtdIndia
Premier Pharmaceuticals Marketing Corp.Importer: AMB HK Enterprises Inc.
DRP-15342-06
Jun 25, 2029
RadapexDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Private LimitedIndia
HLM Pharmaceutical Inc.Importer: AMB HK Enterprises Inc.
DRP-15342-03
Jun 25, 2029
RentosDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Bewell Nutraceuticals Corp.Importer: Ollen Pharma Trading, Inc.
DRP-11789-09
Apr 29, 2027
RentosDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Bewell Nutraceuticals Corp.Importer: Ambica International Corporation
DRP-15483-12
Jul 16, 2029
RentosDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30’s)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Bewell Nutraceuticals Corp.Importer: Nelpa Lifesciences, Inc.
DRP-17182-03
Oct 16, 2030
RetaflozinDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Reta DrugImporter: Orange Biotec Inc.
DRP-15710-01
Sep 4, 2029
RetaliflozinDapagliflozin (as propanediol monohydrate)
10mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
4Care Lifescience Private LimitedIndia
Reta DrugImporter: Aglobal Care, Inc.
DRP-17907-01
Apr 7, 2031
RitedapagDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-15483-07
Jul 16, 2029
SaflozinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Shanghai Pharma (Philippines) Inc.Importer: Ambica International Corporation
DRP-15483-21
Jul 16, 2029
SciGliFloDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt.Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-15483-01
Jul 16, 2029
Seren 10Dapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Zydus Healthcare Philippines, Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-10721-07
Nov 11, 2031
Seren 10Dapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's; and Box of 10's as physician's sample)
RxVAT-exempt
Alidac Healthcare (Myanmar) Ltd.Myanmar
Zydus Healthcare Philippines Inc.
DRP-16752
Jul 11, 2030
Seren 5Dapagliflozin (as propanediol monohydrate)
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's; and Box of 10's as physician's sample)
RxVAT-exempt
Alidac Healthcare (Myanmar) Ltd.Myanmar
Zydus Healthcare Philippines Inc.
DRP-16753
Aug 8, 2030
SolglifDapagliflozin (as propanediol monohydrate)
10 mg Film-coated tabletAlu/Alu Blsiter Pack x 10's (Box of 30's)
RxVAT-exempt
4Care Lifescience Private LimitedIndia
Bellus Life Solutions, Inc.Importer: AGLOBAL CARE, INC.
DRP-17907-05
Apr 7, 2031
SugressaDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Baroque Pharmaceuticals Private LimitedIndia
Orient Pearl Med Pharma Inc.Importer: Amb Hk Enterprises Inc.
DRP-15342-09
Jun 25, 2029
TechnodapDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
One Technodrug Life Sciences Inc.Importer: Ambica International Corporation
DRP-15483-18
Jul 16, 2029
TheraglifDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Ratnatris Pharmaceuticals Private LimitedIndia
Therapevo Farmaco Pharma And Medical Supplies TradingImporter: Medinova Pharmaceutical Inc.
DRP-16503-03
Apr 2, 2030
TitanflozinDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Titanium PharmaImporter: Ambica International Corporation
DRP-15483-22
Jul 16, 2029
UnbrandedDapagliflozin (as propanediol monohydrate)
10 mg Film-Coated TabletAlu/Alu Blister Pack x 14's Box of 28's
RxVAT-exempt
AstraZeneca Pharmaceuticals LPUSA
Philusa CorporationImporter: AstraZeneca Pharmaceuticals (Phils.), Inc.Trader: AstraZeneca UK Ltd.
DRP-9916-01
Feb 10, 2029
UnbrandedDapagliflozin
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-10720
Nov 11, 2031
XigazinDapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Chira Pharmaceuticals, Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-10721-09
Nov 11, 2031
(no brand name)Dapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Aldril Pharmaecuticals, Inc.
DR-XY49698
Apr 23, 2031
(no brand name)Dapagliflozin
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DR-XY49699
Apr 23, 2031
(no brand name)Dapagliflozin (as propanediol monohydrate)
5 mg Film-Coated TabletAlu-Alu Blister Pack x 10 tablets (Box of 30's)
RxVAT-exempt
ACI HealthCare LimitedBangladesh
Firmlink Pharma Phils. Co.
DR-XY49711
May 13, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Tablets: • 5 mg, yellow, biconvex, round, film-coated tablets with “5” engraved on one side and “1427” engraved on the other side. • 10 mg, yellow, biconvex, diamond-shaped, film-coated tablets with “10” engraved on one side and “1428” engraved on the other side. • Tablets: 5 mg and 10 mg (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis: Consider ketone monitoring in patients with type 1 diabetes mellitus and consider ketone monitoring in others at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue FARXIGA if ketoacidosis is suspected. Monitor patients for resolution of ketoacidosis before restarting. (5.1)
  • • Volume depletion: Before initiating FARXIGA, assess volume status and renal function in the elderly, patients with renal impairment or low systolic blood pressure, and in patients on diuretics. Monitor for signs and symptoms during therapy. (5.2)
  • • Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections: Monitor patients for signs and symptoms of genitourinary infections and treat promptly, if indicated. Immediately evaluate patients presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise, for necrotizing fasciitis and if suspected, discontinue FARXIGA, and promptly institute appropriate medical and/or surgical intervention (5.3)
  • • Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with FARXIGA. (5.4)
5.1 Diabetic Ketoacidosis in Patients with Type 1

5.1 Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis In patients with type 1 diabetes mellitus, FARXIGA significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond the background rate. In placebo-controlled trials of patients with type 1 diabetes mellitus, the risk of ketoacidosis was markedly increased in patients who received sodium-glucose cotransporter 2 (SGLT2) inhibitors compared to patients who received placebo.

FARXIGA is not indicated for glycemic control in patients with type 1 diabetes mellitus. Type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are also risk factors for ketoacidosis. There have been postmarketing reports of fatal events of ketoacidosis in patients with type 2 diabetes mellitus using SGLT2 inhibitors, including FARXIGA.

Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse. Signs and symptoms are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath.

Blood glucose levels at presentation may be below those typically expected for diabetic ketoacidosis (e.g., less than 250 mg/dL). Ketoacidosis and glucosuria may persist longer than typically expected. Urinary glucose excretion persists for 3 days after discontinuing FARXIGA [see Clinical Pharmacology (12.2)]; however, there have been postmarketing reports of ketoacidosis and/or glucosuria lasting greater than 6 days and some up to 2 weeks after discontinuation of SGLT2 inhibitors.

Consider ketone monitoring in patients with type 1 diabetes mellitus and consider ketone monitoring in others at risk for ketoacidosis if indicated by the clinical situation. Assess for ketoacidosis regardless of presenting blood glucose levels in patients who present with signs and symptoms consistent with severe metabolic acidosis.

If ketoacidosis is suspected, discontinue FARXIGA, promptly evaluate, and treat ketoacidosis, if confirmed. Monitor patients for resolution of ketoacidosis before restarting FARXIGA. Withhold FARXIGA, if possible, in temporary clinical situations that could predispose patients to ketoacidosis. Resume FARXIGA when the patient is clinically stable and has resumed oral intake [see Dosage and Administration (2.4)].

Educate all patients on the signs and symptoms of ketoacidosis and instruct patients to discontinue FARXIGA and seek medical attention immediately if signs and symptoms occur.

5.2 Volume Depletion

5.2 Volume Depletion FARXIGA can cause intravascular volume depletion which may sometimes manifest as symptomatic hypotension or acute transient changes in creatinine. There have been post-marketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors, including FARXIGA.

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m²), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. Before initiating FARXIGA in patients with one or more of these characteristics, assess volume status and renal function. Monitor for signs and symptoms of hypotension, and renal function after initiating therapy.

5.3 Genitourinary

5.3 Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections FARXIGA increases urinary glucose excretion [see Clinical Pharmacology (12.2)] and increases the risk of genitourinary infections including urinary tract infections and genital mycotic infections in both male and female patients [see Adverse Reactions (6.1)]. Serious genitourinary infections, including urosepsis, pyelonephritis, and necrotizing fasciitis of the perineum (Fournier’s gangrene, a rare life-threatening infection requiring urgent surgical intervention), have occurred in patients receiving SGLT2 inhibitors, including FARXIGA [see Adverse Reactions (6.2)].

Cases have required hospitalization. In patients with Fournier’s gangrene, serious outcomes have included multiple surgeries and death. Patients with a history of genitourinary infections are more likely to develop genitourinary infections when using FARXIGA. Monitor patients for signs and symptoms of genitourinary infections and treat promptly, if indicated.

Immediately evaluate patients presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise, for necrotizing fasciitis. If suspected, discontinue FARXIGA and promptly institute appropriate medical and/or surgical intervention.

5.4 Hypoglycemia with Concomitant Use with Insulin

5.4 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues Insulin and insulin secretagogues (e.g., sulfonylureas) are known to cause hypoglycemia. FARXIGA may increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue [see Adverse Reactions (6.1)]. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with FARXIGA [see Drug Interactions (7)].

Drug interactions

Drug or classSeverityEffectWhat to do
DiureticsAdjust or monitorAdditive volume depletion.Assess volume status and consider diuretic dose reduction; monitor kidney function.
Insulin or insulin secretagogues (e.g., sulfonylureas)Adjust or monitorMore hypoglycemia.Lower insulin or secretagogue doses may be needed.
LithiumAdjust or monitorLower serum lithium.Check lithium levels more often when starting or changing the dose.
Urine glucose and 1,5-anhydroglucitol testsMinorPositive urine glucose; unreliable 1,5-AG.Use other methods to monitor glycemic control.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Table 4: Clinically Relevant Interactions with FARXIGA Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when FARXIGA is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4)]. Intervention Concomitant use may require lower doses of insulin or the insulin secretagogue to reduce the risk of hypoglycemia.

Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during FARXIGA initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests.

Intervention Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control. Interference with 1,5-anhydroglucitol (1,5-AG) Assay Clinical Impact Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.

Intervention Monitoring glycemic control with 1,5-AG assay is not recommended. Use alternative methods to monitor glycemic control.

  • See full prescribing information for information on drug interactions and interference of FARXIGA with laboratory tests. (7)

Drug Interactions In Vitro Assessment of Drug Interactions In in vitro studies, dapagliflozin and dapagliflozin 3-O-glucuronide neither inhibited CYP 1A2, 2C9, 2C19, 2D6, or 3A4, nor induced CYP 1A2, 2B6, or 3A4. Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) active transporter, and dapagliflozin 3-O-glucuronide is a substrate for the OAT3 active transporter.

Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. Overall, dapagliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are P-gp, OCT2, OAT1, or OAT3 substrates. Effects of Other Drugs on Dapagliflozin Table 5 shows the effect of coadministered drugs on the pharmacokinetics of dapagliflozin in adults.

No dose adjustments are recommended for dapagliflozin. Table 5: Effects of Coadministered Drugs on Dapagliflozin Systemic Exposure Coadministered Drug (Dose Regimen) Single dose unless otherwise noted. Dapagliflozin (Dose Regimen) Effect on Dapagliflozin Exposure [% Change (90% CI)] C max AUC AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses.

No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once daily for 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13% [↑3%, ↑24%] ↑51% [↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, respectively, with coadministration compared to dapagliflozin administered alone (geometric mean ratio of test: reference was lower than 0.80 or higher than 1.25). Effects of Dapagliflozin on Other Drugs Table 6 shows the effect of dapagliflozin on other coadministered drugs in adults.

Dapagliflozin did not meaningfully affect the pharmacokinetics of the coadministered drugs. Table 6: Effects of Dapagliflozin on the Systemic Exposures of Coadministered Drugs Coadministered Drug (Dose Regimen) Single dose unless otherwise noted. Dapagliflozin (Dose Regimen) Effect on Coadministered Drug Exposure (% Change [90% CI]) C max AUC AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses.

No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↓7% [↓25%, ↑15%] ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↑13% [0%, ↑29%] Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once daily for 7 days ↑13% [↓2%, ↑31%] ↑13% [↓1%, ↑30%] Valsartan (320 mg) 20 mg ↓6% [↓24%, ↑16%] ↑5% [↓15%, ↑29%] Simvastatin (40 mg) 20 mg ↔ ↑19% Digoxin (0.25 mg) 20 mg loading dose then 10 mg once daily for 7 days ↔ ↔ Warfarin (25 mg) 20 mg loading dose then 10 mg once daily for 7 days ↔ ↔ ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, respectively, with coadministration compared to the other medicine administered alone (geometric mean ratio of test: reference was lower than 0.80 or higher than 1.25).

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Metabolism The metabolism of dapagliflozin is primarily mediated by UGT1A9;

Drug Interactions In Vitro Assessment of Drug Interactions In in vitro studies, dapagliflozin and dapagliflozin 3-O-glucuronide neither inhibited CYP 1A2, 2C9, 2C19, 2D6, or 3A4, nor induced CYP 1A2, 2B6, or 3A4.

Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) active transporter, and dapagliflozin 3-O-glucuronide is a substrate for the OAT3 active transporter.

Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters.

Overall, dapagliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are P-gp, OCT2, OAT1, or OAT3 substrates.

(7) Drug Interactions In Vitro Assessment of Drug Interactions In in vitro studies, dapagliflozin and dapagliflozin 3-O-glucuronide neither inhibited CYP 1A2, 2C9, 2C19, 2D6, or 3A4, nor induced CYP 1A2, 2B6, or 3A4.

Adverse reactions

Common

  • Female genital mycotic infections, nasopharyngitis, urinary tract infections (≥5%)

Serious

  • Ketoacidosis (type 1 diabetes and other ketoacidosis)
  • Volume depletion
  • Urosepsis, pyelonephritis, Fournier's gangrene
  • Hypoglycemia with insulin or secretagogues
  • Serious hypersensitivity (anaphylaxis, angioedema)
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following important adverse reactions are described below and elsewhere in the labeling: • Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis [see Warnings and Precautions (5.1)] • Volume Depletion [see Warnings and Precautions (5.2)] • Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections [see Warnings and Precautions (5.3)] • Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues [see Warnings and Precautions (5.4)] • Most common adverse reactions (5% or greater incidence) were female genital mycotic infections, nasopharyngitis, and urinary tract infections. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. FARXIGA has been evaluated in clinical trials in adult and pediatric patients aged 10 years and older with type 2 diabetes mellitus, in adult patients with heart failure, and in adult patients with chronic kidney disease.

The overall safety profile of FARXIGA was consistent across the studied indications. No new adverse reactions were identified in the DAPA-HF and DELIVER heart failure trials, or in the DAPA-CKD trial in patients with chronic kidney disease. Severe hypoglycemia and diabetic ketoacidosis (DKA) were observed only in patients with diabetes mellitus.

Clinical Trials for Glycemic Control in Adult Patients with Type 2 Diabetes Mellitus Pool of 12 Placebo-Controlled Adult Trials for FARXIGA 5 and 10 mg for Glycemic Control The data in Table 1 is derived from 12 glycemic control placebo-controlled trials in adult patients with type 2 diabetes mellitus ranging from 12 to 24 weeks. In 4 trials FARXIGA was used as monotherapy, and in 8 trials FARXIGA was used as add-on to background antidiabetic therapy or as combination therapy with metformin [see Clinical Studies (14.1)].

These data reflect exposure of 2338 adult patients to FARXIGA with a mean exposure duration of 21 weeks. Patients received placebo (N=1393), FARXIGA 5 mg (N=1145), or FARXIGA 10 mg (N=1193) once daily. The mean age of the population was 55 years and 2% were older than 75 years of age. Fifty percent (50%) of the population were male; 81% were White, 14% were Asian, and 3% were Black or African American.

At baseline, the population had diabetes for an average of 6 years, had a mean hemoglobin A1c (HbA1c) of 8.3%, and 21% had established microvascular complications of diabetes. Baseline renal function was normal or mildly impaired in 92% of patients and moderately impaired in 8% of patients (mean eGFR 86 mL/min/1.73 m²).

Table 1 shows common adverse reactions in adults associated with the use of FARXIGA. These adverse reactions were not present at baseline, occurred more commonly on FARXIGA than on placebo, and occurred in at least 2% of patients treated with either FARXIGA 5 mg or FARXIGA 10 mg. Table 1: Adverse Reactions in Placebo-Controlled Trials of Glycemic Control Reported in ≥2% of Adults Treated with FARXIGA Adverse Reaction % of Patients Pool of 12 Placebo-Controlled Trials Placebo N=1393 FARXIGA 5 mg N=1145 FARXIGA 10 mg N=1193 Female genital mycotic infections Genital mycotic infections include the following adverse reactions, listed in order of frequency reported for females: vulvovaginal mycotic infection, vaginal infection, vulvovaginal candidiasis, vulvovaginitis, genital infection, genital candidiasis, fungal genital infection, vulvitis, genitourinary tract infection, vulval abscess, and vaginitis bacterial.

(N for females: Placebo=677, FARXIGA 5 mg=581, FARXIGA 10 mg=598). 1.5 8.4

6.9 Nasopharyngitis 6

6.9 Nasopharyngitis 6.2 6.6

6.3 Urinary

6.3 Urinary tract infections Urinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis. 3.7 5.7 4.3 Back pain 3.2 3.1 4.2 Increased urination Increased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased. 1.7 2.9 3.8 Male genital mycotic infections Genital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, and posthitis. (N for males: Placebo=716, FARXIGA 5 mg=564, FARXIGA 10 mg=595). 0.3 2.8 2.7 Nausea 2.4 2.8 2.5 Influenza 2.3 2.7 2.3 Dyslipidemia 1.5 2.1 2.5 Constipation 1.5 2.2 1.9 Discomfort with urination 0.7 1.6 2.1 Pain in extremity 1.4 2.0 1.7 Pool of 13 Placebo-Controlled Adult Trials for FARXIGA 10 mg for Glycemic Control FARXIGA 10 mg was also evaluated in a larger glycemic control placebo-controlled trial pool in adult patients with type 2 diabetes mellitus.

This pool combined 13 placebo-controlled trials, including 3 monotherapy trials, 9 add-on to background antidiabetic therapy trials, and an initial combination with metformin trial. Across these 13 trials, 2360 patients were treated once daily with FARXIGA 10 mg for a mean duration of exposure of 22 weeks. The mean age of the population was 59 years and 4% were older than 75 years.

Fifty-eight percent (58%) of the population were male; 84% were White, 9% were Asian, and 3% were Black or African American. At baseline, the population had diabetes for an average of 9 years, had a mean HbA1c of 8.2%, and 30% had established microvascular disease. Baseline renal function was normal or mildly impaired in 88% of patients and moderately impaired in 11% of patients (mean eGFR 82 mL/min/1.73 m²).

Other Adverse Reactions in Adult Patients with Type 2 Diabetes Mellitus Volume Depletion FARXIGA causes an osmotic diuresis, which may lead to a reduction in intravascular volume. Adverse reactions related to volume depletion (including reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension) in adult patients with type 2 diabetes mellitus for the 12-trial and 13-trial, short-term, placebo-controlled pools and for the DECLARE trial are shown in Table 2 [see Warnings and Precautions (5.2)].

Table 2: Adverse Reactions Related to Volume Depletion Volume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension. in Clinical Trials in Adults with Type 2 Diabetes Mellitus with FARXIGA Pool of 12 Placebo-Controlled Trials Pool of 13 Placebo-Controlled Trials DECLARE Trial Placebo FARXIGA 5 mg FARXIGA 10 mg Placebo FARXIGA 10 mg Placebo FARXIGA 10 mg Overall population N (%) N=1393 5 (0.4%) N=1145 7 (0.6%) N=1193 9 (0.8%) N=2295 17 (0.7%) N=2360 27 (1.1%) N=8569 207 (2.4%) N=8574 213 (2.5%) Patient Subgroup n (%) Patients on loop diuretics n=55 1 (1.8%) n=40 0 n=31 3 (9.7%) n=267 4 (1.5%) n=236 6 (2.5%) n=934 57 (6.1%) n=866 57 (6.6%) Patients with moderate renal impairment with eGFR ≥30 and <60 mL/min/1.73 m² n=107 2 (1.9%) n=107 1 (0.9%) n=89 1 (1.1%) n=268 4 (1.5%) n=265 5 (1.9%) n=658 30 (4.6%) n=604 35 (5.8%) Patients ≥65 years of age n=276 1 (0.4%) n=216 1 (0.5%) n=204 3 (1.5%) n=711 6 (0.8%) n=665 11 (1.7%) n=3950 121 (3.1%) n=3948 117 (3.0%) Hypoglycemia The frequency of hypoglycemia by trial in adult patients with type 2 diabetes mellitus [see Clinical Studies (14.1)] is shown in Table 3. Hypoglycemia was more frequent when FARXIGA was added to sulfonylurea or insulin [see Warnings and Precautions (5.4)].

Table 3: Incidence of Severe Hypoglycemia Severe episodes of hypoglycemia were defined as episodes of severe impairment in consciousness or behavior, requiring external (third party) assistance, and with prompt recovery after intervention regardless of glucose level. and Hypoglycemia with Glucose < 54 mg/dL Episodes of hypoglycemia with glucose <54 mg/dL (3 mmol/L) were defined as reported episodes of hypoglycemia meeting the glucose criteria that did not also qualify as a severe episode. in Controlled Glycemic Control Clinical Trials in Adults with Type 2 Diabetes Mellitus Placebo/Active Control FARXIGA 5 mg FARXIGA 10 mg Monotherapy (24 weeks) N=75 N=64 N=70 Severe [n (%)] 0 0 0 Glucose <54 mg/dL [n (%)] 0 0 0 Add-on to Metformin (24 weeks) N=137 N=137 N=135 Severe [n (%)] 0 0 0 Glucose <54 mg/dL [n (%)] 0 0 0 Add-on to Glimepiride (24 weeks) N=146 N=145 N=151 Severe [n (%)] 0 0 0 Glucose <54 mg/dL [n (%)] 1 (0.7) 3 (2.1) 5 (3.3) Add-on to Metformin and a Sulfonylurea (24 Weeks) N=109 - N=109 Severe [n (%)] 0 - 0 Glucose <54 mg/dL [n (%)] 3 (2.8) - 7 (6.4) Add-on to Pioglitazone (24 weeks) N=139 N=141 N=140 Severe [n (%)] 0 0 0 Glucose <54 mg/dL [n (%)] 0 1 (0.7) 0 Add-on to DPP4 inhibitor (24 weeks) N=226 – N=225 Severe [n (%)] 0 – 1 (0.4) Glucose <54 mg/dL [n (%)] 1 (0.4) – 1 (0.4) Add-on to Insulin with or without other OADs OAD = oral antidiabetic therapy. (24 weeks) N=197 N=212 N=196 Severe [n (%)] 1 (0.5) 2 (0.9) 2 (1.0) Glucose <54 mg/dL [n (%)] 43 (21.8) 55 (25.9) 45 (23.0) In the DECLARE trial [see Clinical Studies (14.3)], severe events of hypoglycemia were reported in 58 (0.7%) out of 8574 adult patients treated with FARXIGA and 83 (1.0%) out of 8569 adult patients treated with placebo.

Genital Mycotic Infections In the glycemic control trials in adults, genital mycotic infections were more frequent with FARXIGA treatment. Genital mycotic infections were reported in 0.9% of patients on placebo, 5.7% on FARXIGA 5 mg, and 4.8% on FARXIGA 10 mg, in the 12-trial placebo-controlled pool. Discontinuation from trial due to genital infection occurred in 0% of placebo-treated patients and 0.2% of patients treated with FARXIGA 10 mg.

Infections were more frequently reported in females than in males (see Table 1). The most frequently reported genital mycotic infections were vulvovaginal mycotic infections in females and balanitis in males. Patients with a history of genital mycotic infections were more likely to have a genital mycotic infection during the trial than those with no prior history (10.0%, 23.1%, and 25.0% versus 0.8%, 5.9%, and 5.0% on placebo, FARXIGA 5 mg, and FARXIGA 10 mg, respectively).

In the DECLARE trial [see Clinical Studies (14.3)], serious genital mycotic infections were reported in <0.1% of patients treated with FARXIGA and <0.1% of patients treated with placebo. Genital mycotic infections that caused trial drug discontinuation were reported in 0.9% of patients treated with FARXIGA and <0.1% of patients treated with placebo.

Hypersensitivity Reactions Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) were reported with FARXIGA treatment. In glycemic control trials in adults, serious anaphylactic reactions and severe cutaneous adverse reactions and angioedema were reported in 0.2% of comparator-treated patients and 0.3% of FARXIGA-treated patients.

If hypersensitivity reactions occur, discontinue use of FARXIGA; treat per standard of care and monitor until signs and symptoms resolve. Ketoacidosis in Patients with Diabetes Mellitus In the DECLARE trial [see Clinical Studies (14.3)], events of diabetic ketoacidosis (DKA) were reported in 27 out of 8574 adult patients in the FARXIGA-treated group and 12 out of 8569 adult patients in the placebo group.

The events were evenly distributed over the trial period. Laboratory Tests in Adult Patients with Type 2 Diabetes Mellitus Increases in Serum Creatinine and Decreases in eGFR Initiation of SGLT2 inhibitors, including FARXIGA causes a small increase in serum creatinine and decrease in eGFR. These changes in serum creatinine and eGFR generally occur within two weeks of starting therapy and then stabilize regardless of baseline kidney function.

Changes that do not fit this pattern should prompt further evaluation to exclude the possibility of acute kidney injury [see Warnings and Precautions (5.2)]. In two trials that included adult patients with type 2 diabetes mellitus with moderate renal impairment, the acute effect on eGFR reversed after treatment discontinuation, suggesting acute hemodynamic changes may play a role in the renal function changes observed with FARXIGA.

Increase in Hematocrit In the pool of 13 placebo-controlled trials of glycemic control, increases from baseline in mean hematocrit values were observed in FARXIGA-treated adult patients starting at Week 1 and continuing up to Week 16, when the maximum mean difference from baseline was observed. At Week 24, the mean changes from baseline in hematocrit were -0.33% in the placebo group and 2.30% in the FARXIGA 10 mg group.

By Week 24, hematocrit values >55% were reported in 0.4% of placebo-treated patients and 1.3% of FARXIGA 10 mg-treated patients. Increase in Low-Density Lipoprotein Cholesterol In the pool of 13 placebo-controlled trials of glycemic control, changes from baseline in mean lipid values were reported in FARXIGA-treated adult patients compared to placebo-treated patients.

Mean percent changes from baseline at Week 24 were 0.0% versus 2.5% for total cholesterol, and -1.0% versus 2.9% for LDL cholesterol in the placebo and FARXIGA 10 mg groups, respectively. In the DECLARE trial [see Clinical Studies (14.3)], mean changes from baseline after 4 years were 0.4 mg/dL versus -4.1 mg/dL for total cholesterol, and -2.5 mg/dL versus -4.4 mg/dL for LDL cholesterol, in FARXIGA-treated and the placebo groups, respectively.

Decrease in Serum Bicarbonate In a trial of concomitant therapy of FARXIGA 10 mg with exenatide extended-release (on a background of metformin) in adults, four patients (1.7%) on concomitant therapy had a serum bicarbonate value of less than or equal to 13 mEq/L compared to one each (0.4%) in the FARXIGA and exenatide-extended release treatment groups [see Warnings and Precautions (5.1)]. Clinical Trial in Pediatric Patients with Type 2 Diabetes Mellitus The FARXIGA safety profile observed in a 26-week placebo-controlled clinical trial with a 26-week extension in 157 pediatric patients aged 10 years and older with type 2 diabetes mellitus was similar to that observed in adults [see Clinical Studies (14.2)].

6.2 Postmarketing Experience

6.2 Postmarketing Experience Additional adverse reactions have been identified during post-approval use of FARXIGA. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Infections: Necrotizing fasciitis of the perineum (Fournier’s Gangrene), urosepsis and pyelonephritis Metabolism and Nutrition Disorders: Ketoacidosis Renal and Urinary Disorders: Acute kidney injury Skin and Subcutaneous Tissue Disorders: Rash

Adverse reaction frequency tables (US label) US FDA label
Table 1: Adverse Reactions in Placebo-Controlled Trials of Glycemic Control Reported in ≥2% of Adults Treated with FARXIGA
Adverse Reaction% of Patients
Pool of 12 Placebo-Controlled Trials
Placebo N=1393FARXIGA 5 mg N=1145FARXIGA 10 mg N=1193
Female genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for females: vulvovaginal mycotic infection, vaginal infection, vulvovaginal candidiasis, vulvovaginitis, genital infection, genital candidiasis, fungal genital infection, vulvitis, genitourinary tract infection, vulval abscess, and vaginitis bacterial. (N for females: Placebo=677, FARXIGA 5 mg=581, FARXIGA 10 mg=598).1.58.46.9
Nasopharyngitis6.26.66.3
Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.3.75.74.3
Back pain3.23.14.2
Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.1.72.93.8
Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, and posthitis. (N for males: Placebo=716, FARXIGA 5 mg=564, FARXIGA 10 mg=595).0.32.82.7
Nausea2.42.82.5
Influenza2.32.72.3
Dyslipidemia1.52.12.5
Constipation1.52.21.9
Discomfort with urination 0.71.62.1
Pain in extremity1.42.01.7
Table 2: Adverse Reactions Related to Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension. in Clinical Trials in Adults with Type 2 Diabetes Mellitus with FARXIGA
Pool of 12 Placebo-Controlled TrialsPool of 13 Placebo-Controlled TrialsDECLARE Trial
PlaceboFARXIGA 5 mgFARXIGA 10 mgPlaceboFARXIGA 10 mgPlaceboFARXIGA 10 mg
Overall population N (%)N=1393 5 (0.4%)N=1145 7 (0.6%)N=1193 9 (0.8%)N=2295 17 (0.7%)N=2360 27 (1.1%)N=8569 207 (2.4%)N=8574 213 (2.5%)
Patient Subgroup n (%)
Patients on loop diureticsn=55 1 (1.8%)n=40 0 n=31 3 (9.7%)n=267 4 (1.5%)n=236 6 (2.5%)n=934 57 (6.1%)n=866 57 (6.6%)
Patients with moderate renal impairment with eGFR ≥30 and <60 mL/min/1.73 m2n=107 2 (1.9%)n=107 1 (0.9%)n=89 1 (1.1%)n=268 4 (1.5%)n=265 5 (1.9%)n=658 30 (4.6%)n=604 35 (5.8%)
Patients ≥65 years of agen=276 1 (0.4%)n=216 1 (0.5%)n=204 3 (1.5%)n=711 6 (0.8%)n=665 11 (1.7%)n=3950 121 (3.1%)n=3948 117 (3.0%)
Table 3: Incidence of Severe HypoglycemiaSevere episodes of hypoglycemia were defined as episodes of severe impairment in consciousness or behavior, requiring external (third party) assistance, and with prompt recovery after intervention regardless of glucose level. and Hypoglycemia with Glucose < 54 mg/dLEpisodes of hypoglycemia with glucose <54 mg/dL (3 mmol/L) were defined as reported episodes of hypoglycemia meeting the glucose criteria that did not also qualify as a severe episode. in Controlled Glycemic Control Clinical Trials in Adults with Type 2 Diabetes Mellitus
Placebo/Active ControlFARXIGA 5 mgFARXIGA 10 mg
Monotherapy (24 weeks)N=75N=64N=70
Severe [n (%)]000
Glucose <54 mg/dL [n (%)]000
Add-on to Metformin (24 weeks)N=137N=137N=135
Severe [n (%)]000
Glucose <54 mg/dL [n (%)]000
Add-on to Glimepiride (24 weeks)N=146N=145N=151
Severe [n (%)]000
Glucose <54 mg/dL [n (%)]1 (0.7)3 (2.1)5 (3.3)
Add-on to Metformin and a Sulfonylurea (24 Weeks)N=109-N=109
Severe [n (%)]0-0
Glucose <54 mg/dL [n (%)]3 (2.8)-7 (6.4)
Add-on to Pioglitazone (24 weeks)N=139N=141N=140
Severe [n (%)]000
Glucose <54 mg/dL [n (%)]01 (0.7)0
Add-on to DPP4 inhibitor (24 weeks)N=226–N=225
Severe [n (%)]0–1 (0.4)
Glucose <54 mg/dL [n (%)]1 (0.4)–1 (0.4)
Add-on to Insulin with or without other OADsOAD = oral antidiabetic therapy. (24 weeks)N=197N=212N=196
Severe [n (%)]1 (0.5)2 (0.9)2 (1.0)
Glucose <54 mg/dL [n (%)]43 (21.8)55 (25.9)45 (23.0)

Monitoring parameters

  • Assess kidney function and volume status before starting; correct volume depletion. Expect an early small eGFR dip. Withhold at least 3 days before surgery or prolonged fasting (label); watch for ketoacidosis. Kidney
  • Kidney function before starting and as indicated
  • Volume status before starting (correct depletion)
  • Ketones/ketoacidosis signs when acutely ill; withhold at least 3 days before surgery or prolonged fasting
  • Genital and urinary infection symptoms
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on animal data showing adverse renal effects, FARXIGA is not recommended during the second and third trimesters of pregnancy. Limited data with FARXIGA in pregnant women are not sufficient to determine drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes and untreated heart failure in pregnancy (see clinical considerations).

In animal studies, adverse renal pelvic and tubule dilatations, that were not fully reversible, were observed in rats when dapagliflozin was administered during a period of renal development corresponding to the late second and third trimesters of human pregnancy, at all doses tested; the lowest of which provided an exposure 15-times the 10 mg clinical dose (see Data). The estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes with a HbA1c greater than 7% and has been reported to be as high as 20 to 25% in women with HbA1c greater than 10%.

The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryofetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery and delivery complications.

Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Data Animal Data Dapagliflozin dosed directly to juvenile rats from postnatal day (PND) 21 until PND 90 at doses of 1, 15, or 75 mg/kg/day, increased kidney weights and increased the incidence of renal pelvic and tubular dilatations at all dose levels.

Exposure at the lowest dose tested was 15-times the 10 mg clinical dose (based on AUC). The renal pelvic and tubular dilatations observed in juvenile animals did not fully reverse within a 1-month recovery period. In a prenatal and postnatal development study, dapagliflozin was administered to maternal rats from gestation day 6 through lactation day 21 at doses of 1, 15, or 75 mg/kg/day, and pups were indirectly exposed in utero and throughout lactation.

Increased incidence or severity of renal pelvic dilatation was observed in 21-day-old pups offspring of treated dams at 75 mg/kg/day (maternal and pup dapagliflozin exposures were 1415-times and 137-times, respectively, the human values at the 10 mg clinical dose, based on AUC). Dose-related reductions in pup body weights were observed at greater or equal to 29-times the 10 mg clinical dose (based on AUC).

No adverse effects on developmental endpoints were noted at 1 mg/kg/day (19-times the 10 mg clinical dose, based on AUC). These outcomes occurred with drug exposure during periods of renal development in rats that corresponds to the late second and third trimester of human development. In embryofetal development studies in rats and rabbits, dapagliflozin was administered throughout organogenesis, corresponding to the first trimester of human pregnancy.

In rats, dapagliflozin was neither embryolethal nor teratogenic at doses up to 75 mg/kg/day (1441-times the 10 mg clinical dose, based on AUC). Dose-related effects on the rat fetus (structural abnormalities and reduced body weight) occurred only at higher dosages, equal to or greater than 150 mg/kg (more than 2344-times the 10 mg clinical dose, based on AUC), which were associated with maternal toxicity.

No developmental toxicities were observed in rabbits at doses up to 180 mg/kg/day (1191-times the 10 mg clinical dose, based on AUC).

Mechanism of action

12.1 Mechanism of Action Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion.

Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of sympathetic activity, and decreased intraglomerular pressure which is believed to be mediated by increased tubuloglomerular feedback.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics General Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following the administration of dapagliflozin (see Figure 1). Dapagliflozin doses of 5 or 10 mg per day in patients with type 2 diabetes mellitus for 12 weeks resulted in excretion of approximately 70 grams of glucose in the urine per day at Week 12.

A near maximum glucose excretion was observed at the dapagliflozin daily dosage of 20 mg. This urinary glucose excretion with dapagliflozin also results in increases in urinary volume [see Adverse Reactions (6.1)]. After discontinuation of dapagliflozin, on average, the elevation in urinary glucose excretion approaches baseline by about 3 days for the 10 mg dosage.

Figure 1: Scatter Plot and Fitted Line of Change from Baseline in 24-Hour Urinary Glucose Amount versus Dapagliflozin Dose in Healthy Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM) (Semi-Log Plot) Figure 1 Cardiac Electrophysiology Dapagliflozin was not associated with clinically meaningful prolongation of QTc interval at daily doses up to 150 mg (15-times the recommended maximum dose) in a study of healthy subjects. In addition, no clinically meaningful effect on QTc interval was observed following single doses of up to 500 mg (50-times the recommended maximum dose) of dapagliflozin in healthy subjects.

Pharmacokinetics

Key PK parameters

Bioavailability78% (10 mg)
Time to peakWithin 2 hours (fasting)
Half-lifeAbout 12.9 hours (single 10 mg dose)
Protein bindingAbout 91%
Metabolism (CYP, transporters)Mainly UGT1A9 to inactive dapagliflozin 3-O-glucuronide; CYP minor
Active metabolitesNone (3-O-glucuronide inactive)
Renal excretion kidney75% of radioactivity in urine (under 2% as parent); 21% in feces
Dialyzability kidneyUnknown: removal by hemodialysis not studied (label).
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Following a single 50 mg dose of [ 14 C]-dapagliflozin, 75% and 21% total radioactivity is excreted in urine and feces, respectively.

In urine, less than 2% of the dose is excreted as parent drug.

In feces, approximately 15% of the dose is excreted as parent drug.

The mean plasma terminal half-life (t ½ ) for dapagliflozin is approximately 12.9 hours following a single oral dose of FARXIGA 10 mg.

Higher systemic exposure of dapagliflozin in patients with type 2 diabetes mellitus with renal impairment did not result in a correspondingly higher 24-hour urinary glucose excretion.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Following oral administration of dapagliflozin, the maximum plasma concentration (C max) is usually attained within 2 hours under fasting state. The C max and AUC values increase dose proportionally with increase in dapagliflozin dose in the therapeutic dose range. The absolute oral bioavailability of dapagliflozin following the administration of a 10 mg dose is 78%.

Administration of dapagliflozin with a high-fat meal decreases its C max by up to 50% and prolongs T max by approximately 1 hour but does not alter AUC as compared with the fasted state. These changes are not considered to be clinically meaningful and dapagliflozin can be administered with or without food Distribution Dapagliflozin is approximately 91% protein bound.

Protein binding is not altered in patients with renal or hepatic impairment. Metabolism The metabolism of dapagliflozin is primarily mediated by UGT1A9; CYP-mediated metabolism is a minor clearance pathway in humans. Dapagliflozin is extensively metabolized, primarily to yield dapagliflozin 3-O-glucuronide, which is an inactive metabolite.

Dapagliflozin 3-O-glucuronide accounted for 61% of a 50 mg [14 C]-dapagliflozin dose and is the predominant drug-related component in human plasma. Elimination Dapagliflozin and related metabolites are primarily eliminated via the renal pathway. Following a single 50 mg dose of [14 C]-dapagliflozin, 75% and 21% total radioactivity is excreted in urine and feces, respectively.

In urine, less than 2% of the dose is excreted as parent drug. In feces, approximately 15% of the dose is excreted as parent drug. The mean plasma terminal half-life (t ½) for dapagliflozin is approximately 12.9 hours following a single oral dose of FARXIGA 10 mg. Specific Populations Pediatric Patients The pharmacokinetics and pharmacodynamics (glucosuria) of dapagliflozin in pediatric patients aged 10 to 17 years with type 2 diabetes mellitus were similar to those observed in adult patients with same renal function.

Effects of Age, Gender, Race, and Body Weight on Pharmacokinetics Based on a population pharmacokinetic analysis, age, gender, race, and body weight do not have a clinically meaningful effect on the pharmacokinetics of dapagliflozin and thus, no dose adjustment is recommended. Patients with Renal Impairment At steady state (20 mg once daily dapagliflozin for 7 days), adult patients with type 2 diabetes with mild, moderate, or severe renal impairment (as determined by eGFR) had geometric mean systemic exposures of dapagliflozin that were 45%, 100%, and 200% higher, respectively, as compared to patients with type 2 diabetes mellitus with normal renal function.

There was no meaningful difference in exposure between patients with chronic kidney disease with and without type 2 diabetes. Higher systemic exposure of dapagliflozin in patients with type 2 diabetes mellitus with renal impairment did not result in a correspondingly higher 24-hour urinary glucose excretion. The steady-state 24-hour urinary glucose excretion in patients with type 2 diabetes mellitus and mild, moderate, and severe renal impairment was 42%, 80%, and 90% lower, respectively, than in patients with type 2 diabetes mellitus with normal renal function.

The impact of hemodialysis on dapagliflozin exposure is not known [see Warnings and Precautions (5.2), Use in Specific Populations (8.6), and Clinical Studies (14)] Patients with Hepatic Impairment In adult subjects with mild and moderate hepatic impairment (Child-Pugh classes A and B), mean C max and AUC of dapagliflozin were up to 12% and 36% higher, respectively, as compared to healthy matched control subjects following single-dose administration of 10 mg dapagliflozin. These differences were not considered to be clinically meaningful.

In adult patients with severe hepatic impairment (Child-Pugh class C), mean C max and AUC of dapagliflozin were up to 40% and 67% higher, respectively, as compared to healthy matched controls [see Use in Specific Populations (8.7)]. Drug Interactions In Vitro Assessment of Drug Interactions In in vitro studies, dapagliflozin and dapagliflozin 3-O-glucuronide neither inhibited CYP 1A2, 2C9, 2C19, 2D6, or 3A4, nor induced CYP 1A2, 2B6, or 3A4.

Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) active transporter, and dapagliflozin 3-O-glucuronide is a substrate for the OAT3 active transporter. Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. Overall, dapagliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are P-gp, OCT2, OAT1, or OAT3 substrates.

Effects of Other Drugs on Dapagliflozin Table 5 shows the effect of coadministered drugs on the pharmacokinetics of dapagliflozin in adults. No dose adjustments are recommended for dapagliflozin. Table 5: Effects of Coadministered Drugs on Dapagliflozin Systemic Exposure Coadministered Drug (Dose Regimen) Single dose unless otherwise noted.

Dapagliflozin (Dose Regimen) Effect on Dapagliflozin Exposure [% Change (90% CI)] C max AUC AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses. No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10 mg ↔ ↔ Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once daily for 7 days ↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13% [↑3%, ↑24%] ↑51% [↑44%, ↑58%] ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, respectively, with coadministration compared to dapagliflozin administered alone (geometric mean ratio of test: reference was lower than 0.80 or higher than 1.25).

Effects of Dapagliflozin on Other Drugs Table 6 shows the effect of dapagliflozin on other coadministered drugs in adults. Dapagliflozin did not meaningfully affect the pharmacokinetics of the coadministered drugs. Table 6: Effects of Dapagliflozin on the Systemic Exposures of Coadministered Drugs Coadministered Drug (Dose Regimen) Single dose unless otherwise noted.

Dapagliflozin (Dose Regimen) Effect on Coadministered Drug Exposure (% Change [90% CI]) C max AUC AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses. No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↓7% [↓25%, ↑15%] ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↑13% [0%, ↑29%] Other Medications Hydrochlorothiazide (25 mg) 50 mg ↔ ↔ Bumetanide (1 mg) 10 mg once daily for 7 days ↑13% [↓2%, ↑31%] ↑13% [↓1%, ↑30%] Valsartan (320 mg) 20 mg ↓6% [↓24%, ↑16%] ↑5% [↓15%, ↑29%] Simvastatin (40 mg) 20 mg ↔ ↑19% Digoxin (0.25 mg) 20 mg loading dose then 10 mg once daily for 7 days ↔ ↔ Warfarin (25 mg) 20 mg loading dose then 10 mg once daily for 7 days ↔ ↔ ↔ = no change (geometric mean ratio of test: reference within 0.80 to 1.25); ↓ or ↑ = parameter was lower or higher, respectively, with coadministration compared to the other medicine administered alone (geometric mean ratio of test: reference was lower than 0.80 or higher than 1.25).

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
10 mg film-coated tablet₱25.75per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Dapagliflozin
PNF listing10 mg film-coated tablet
PhilHealth GAMOTYes (listed since July 28, 2025)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. FARXIGA · AstraZeneca Pharmaceuticals LP [US FDA-approved label, version 49, June 3, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PhilHealth Advisory No. 2024-0026, PNF 8th ed. EML 2019 as of November 2, 2022 with newly approved medicines as of April 25, 2024; DOH-DC No. 2023-0169 (included 2023-04-11); https://www.philhealth.gov.ph/advisories/2024/PA2024-0026.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. AstraZeneca Pharmaceuticals LP. (2026). FARXIGA (dapagliflozin) [Prescribing information; US FDA-approved label, NDA202293, set ID 72ad22ae-efe6-4cd6-a302-98aaee423d69, version effective June 3, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69
  7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
  8. de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022). Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care, 45(12), 3075–3090. https://doi.org/10.2337/dci22-0027
  9. American Diabetes Association Professional Practice Committee. (2026). 11. Chronic kidney disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care, 49(Suppl. 1), S246–S260. https://doi.org/10.2337/dc26-S011
  10. Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .